QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Neuronetics, Inc. (STIM)

Healthcare

No action
Fundamental
1
Sentiment
1
Technical
2

Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3, so no long entry can be admitted; both entry types were nevertheless evaluated - a pullback/oversold limit is disqualified as countertrend (price 1.39 below SMA50 2.35 with MACD -0.17 < 0) and a breakout buy-stop above the settled 2026-11-13 high 1.44 is disqualified by overnight-gap risk (max overnight gap 19.1% versus the 5% cap), so no qualifying setup exists.

Analysis as of 2026-11-14· more than 2 trading days ago

Company overview

Neuronetics, Inc. is a medical technology company focused on developing and distributing solutions for neurohealth conditions. Its primary product, the NeuroStar Advanced Therapy System, offers non-surgical treatment for major depressive disorder using transcranial magnetic stimulation. The company operates from Malvern, Pennsylvania, and sells directly to psychiatrists.

Fundamental

very weak
Fundamental1
High risk profile

Neuronetics faces financial distress with a going-concern warning, covenant issues, and recent dilution overshadowing operational improvements.

Too risky to invest at this juncture: an explicit going-concern qualification in the latest 10-Q, a projected breach of the March 2027 revenue covenant under a lien-secured 11.5% credit facility, negative EBITDA and operating cash flow, and roughly a quarter of dilution from an equity offering priced at $1.60 that closed days ago. Operating trends are genuinely improving - Q3 2026 produced the first positive quarterly operating income and positive quarterly operating cash flow in the recent record - but the balance sheet, the covenant timeline and insider selling dominate the near-term risk.

Sentiment

very weak
Sentiment1
Mixed sentiment

Media sentiment is mixed with concerns over dilution and debt, while retail sentiment remains indeterminate.

Dominant near-term driver is the announced $30M underwritten offering priced at $1.60 on 2026-11-11 (18.75M shares plus over-allotment, roughly 24% dilution, proceeds earmarked to repay Perceptive), which closed 2026-11-12 and has left shares at $1.39, about 13% below the deal price; Q3 2026 (announced: revenue +12.5% to $42.0M, adjusted EBITDA +$1.9M) is a genuine but secondary bullish leg the tape did not reward. The sentiment delta is indeterminate because baseline scored coverage holds only one unique item, and the Red-Flag Screen is not clean: an explicit going-concern conclusion in the 2026-11-04 10-Q combined with a distress-context dilutive raise fires the severe red-flag cap.

Technical

weak
Technical2
Downtrend persists

The stock is in a strong downtrend with oversold conditions but no clear reversal signals.

Chart quality is weak and dominated by trend, not by the bounce: price 1.39 sits below SMA20 2.08, SMA50 2.35, SMA200 1.87, EMA9 1.85, EMA21 2.04, WMA9 1.82, WMA21 2.03, DEMA14 1.75 and TEMA14 1.63 - a complete bearish moving-average stack roughly 60% below the 3.44 year high. MACD is negative and expanding (-0.17/-0.08, histogram -0.08) and ADX14 24.57 read together with price below every MA describes a strong, only slowly decelerating downtrend rather than a base. RSI14 31.59 and Williams %R -89.73 are oversold but have not turned up, so the only bullish evidence is a single heavy-volume reversal session (2026-11-13, +14.9%, close 1.39 above the session VWAP 1.31 on 16.3M shares) off the 1.13/1.20 low. That is a bounce, not a trend change, hence technicalScore 2. Independent of the chart, fundamentalScore 1 and qualitativeScore 1 both breach the required floor of 3, so the action is Do Nothing; both a pullback limit (countertrend by rule) and a breakout buy-stop (overnight-gap gate) were evaluated and rejected.

You’re looking at 2026-11-14 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.